Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Neoplasms of the CNS

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 53 articles: HTML format Text format

Single Articles

June 2019
1. COOMANS M, Dirven L, K Aaronson N, Baumert BG, et al
   The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.
   Eur J Cancer. 2019;116:190-198.
   PubMed     Text format     Abstract available
   
   
   May 2019
2. SCHOENMAEKERS J, Hofman P, Bootsma G, Westenend M, et al
   Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
   Eur J Cancer. 2019;115:88-96.
   PubMed     Text format     Abstract available
   
   
   
3. SMITS M, Bendszus M, Collette S, Postma LA, et al
   Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting.
   Eur J Cancer. 2019;114:89-96.
   PubMed     Text format     Abstract available
   
   
   April 2019
4. DE ROJAS T, Clementel E, Giralt J, Cruz O, et al
   Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.
   Eur J Cancer. 2019;114:36-46.
   PubMed     Text format     Abstract available
   
   
   
5. PFAFF E, El Damaty A, Balasubramanian GP, Blattner-Johnson M, et al
   Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.
   Eur J Cancer. 2019;114:27-35.
   PubMed     Text format     Abstract available
   
   
   
6. HARRISON RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, et al
   Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center.
   Eur J Cancer. 2019;112:83-93.
   PubMed     Text format     Abstract available
   
   
   March 2019
7. PAULINE T, Clara A, Bastien O, Stephane D, et al
   Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
   Eur J Cancer. 2019;112:38-46.
   PubMed     Text format     Abstract available
   
   
   February 2019
8. RAUSCHENBERG R, Bruns J, Brutting J, Daubner D, et al
   Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
   Eur J Cancer. 2019;110:11-20.
   PubMed     Text format     Abstract available
   
   
   
9. URSU R, Thomas L, Psimaras D, Chinot O, et al
   Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.
   Eur J Cancer. 2019;109:129-136.
   PubMed     Text format     Abstract available
   
   
   
10. SHINJO D, Matsumoto K, Terashima K, Takimoto T, et al
    Volume effect in paediatric brain tumour resection surgery: analysis of data from the Japanese national inpatient database.
    Eur J Cancer. 2019;109:111-119.
    PubMed     Text format     Abstract available
    
    
    December 2018
11. SUCHORSKA B, Schuller U, Biczok A, Lenski M, et al
    Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
    Eur J Cancer. 2018;107:15-27.
    PubMed     Text format     Abstract available
    
    
    August 2018
12. WITZEL I, Laakmann E, Weide R, Neunhoffer T, et al
    Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
    Eur J Cancer. 2018;102:1-9.
    PubMed     Text format     Abstract available
    
    
    July 2018
13. LE RHUN E, Genbrugge E, Stupp R, Chinot OL, et al
    Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
    Eur J Cancer. 2018;101:95-104.
    PubMed     Text format     Abstract available
    
    
    
14. HABETS EJJ, Taphoorn MJB, Klein M, Vissers T, et al
    The level of reporting of neurocognitive outcomes in randomised controlled trials of brain tumour patients: A systematic review.
    Eur J Cancer. 2018;100:104-125.
    PubMed     Text format     Abstract available
    
    
    June 2018
15. MILSCH L, Gesierich A, Kreft S, Livingstone E, et al
    Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
    Eur J Cancer. 2018;99:58-65.
    PubMed     Text format     Abstract available
    
    
    
16. WELLER M
    Next generation neuro-oncology.
    Eur J Cancer. 2018;96:1-5.
    PubMed     Text format     Abstract available
    
    
    May 2018
17. BONNEAU C, Paintaud G, Tredan O, Dubot C, et al
    Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
    Eur J Cancer. 2018;95:75-84.
    PubMed     Text format     Abstract available
    
    
    April 2018
18. WOLPERT F, Weller M, Berghoff AS, Rushing E, et al
    Diagnostic value of (18)F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.
    Eur J Cancer. 2018;96:64-72.
    PubMed     Text format     Abstract available
    
    
    
19. EL-GALALY TC, Cheah CY, Bendtsen MD, Nowakowski GS, et al
    Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
    Eur J Cancer. 2018;93:57-68.
    PubMed     Text format     Abstract available
    
    
    March 2018
20. ALIFRANGIS C, Wilson P, Shamash J
    Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment
    Eur J Cancer. 2018 Mar 31. pii: S0959-8049(18)30226.
    PubMed     Text format    
    
    
    
21. GAO Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, et al
    Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
    Eur J Cancer. 2018;94:168-178.
    PubMed     Text format     Abstract available
    
    
    February 2018
22. LEVY A, Faivre-Finn C, Hasan B, De Maio E, et al
    Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
    Eur J Cancer. 2018;93:37-46.
    PubMed     Text format     Abstract available
    
    
    December 2017
23. GNEKOW AK, Walker DA, Kandels D, Picton S, et al
    Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report" [Eur J o
    Eur J Cancer. 2017 Dec 13. pii: S0959-8049(17)31415.
    PubMed     Text format    
    
    
    November 2017
24. LE RHUN E, Gorlia T
    Farewell to monomodality treatment in patients with WHO lower grade glioma?
    Eur J Cancer. 2017 Nov 24. pii: S0959-8049(17)31359.
    PubMed     Text format    
    
    
    
25. LORIOT Y, Pagliaro L, Flechon A, Mardiak J, et al
    Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
    Eur J Cancer. 2017;87:140-146.
    PubMed     Text format     Abstract available
    
    
    
26. LE RHUN E, Bertrand N, Dumont A, Tresch E, et al
    Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Eur J Cancer. 2017 Nov 2. pii: S0959-8049(17)31346.
    PubMed     Text format     Abstract available
    
    
    
27. GEORGAKIS MK, Panagopoulou P, Papathoma P, Tragiannidis A, et al
    Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US.
    Eur J Cancer. 2017;86:46-58.
    PubMed     Text format     Abstract available
    
    
    September 2017
28. GATTA G, Peris-Bonet R, Visser O, Stiller C, et al
    Geographical variability in survival of European children with central nervous system tumours.
    Eur J Cancer. 2017;82:137-148.
    PubMed     Text format     Abstract available
    
    
    August 2017
29. PETRELLI F, Ghidini M, Lonati V, Tomasello G, et al
    The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Eur J Cancer. 2017;84:141-148.
    PubMed     Text format     Abstract available
    
    
    
30. GAUDY-MARQUESTE C, Dussouil AS, Carron R, Troin L, et al
    Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Eur J Cancer. 2017;84:44-54.
    PubMed     Text format     Abstract available
    
    
    July 2017
31. JIANG S, Eberhart CG, Zhang Y, Heo HY, et al
    Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas.
    Eur J Cancer. 2017;83:9-18.
    PubMed     Text format     Abstract available
    
    
    
32. BLANK CU, Larkin J, Arance AM, Hauschild A, et al
    Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
    Eur J Cancer. 2017;79:176-184.
    PubMed     Text format     Abstract available
    
    
    June 2017
33. GNEKOW AK, Walker DA, Kandels D, Picton S, et al
    A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report.
    Eur J Cancer. 2017;81:206-225.
    PubMed     Text format     Abstract available
    
    
    
34. GANDHI L, Ignatius Ou SH, Shaw AT, Barlesi F, et al
    Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Eur J Cancer. 2017;82:27-33.
    PubMed     Text format     Abstract available
    
    
    
35. KARREMANN M, Kramer N, Hoffmann M, Wiese M, et al
    Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
    Eur J Cancer. 2017;81:1-8.
    PubMed     Text format     Abstract available
    
    
    
36. DEVIC P, Amini-Adle M, Camdessanche JP, Dalle S, et al
    Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
    Eur J Cancer. 2017;78:103-104.
    PubMed     Text format    
    
    
    May 2017
37. PISCIONE PJ, Bouffet E, Timmons B, Courneya KS, et al
    Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation.
    Eur J Cancer. 2017;80:63-72.
    PubMed     Text format     Abstract available
    
    
    
38. STACCHIOTTI S, Saponara M, Frapolli R, Tortoreto M, et al
    Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    Eur J Cancer. 2017;76:84-92.
    PubMed     Text format     Abstract available
    
    
    April 2017
39. EL-GALALY TC, Villa D, Michaelsen TY, Hutchings M, et al
    The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
    Eur J Cancer. 2017;75:195-203.
    PubMed     Text format     Abstract available
    
    
    
40. GEORGAKIS MK, Kalogirou EI, Liaskas A, Karalexi MA, et al
    Anthropometrics at birth and risk of a primary central nervous system tumour: A systematic review and meta-analysis.
    Eur J Cancer. 2017;75:117-131.
    PubMed     Text format     Abstract available
    
    
    
41. SCHALK E, Zeremski V, Fischer T
    Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma.
    Eur J Cancer. 2017;75:280-283.
    PubMed     Text format    
    
    
    March 2017
42. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Text format     Abstract available
    
    
    
43. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Text format     Abstract available
    
    
    
44. DONIA M, Kimper-Karl ML, Hoyer KL, Bastholt L, et al
    The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.
    Eur J Cancer. 2017;74:89-95.
    PubMed     Text format     Abstract available
    
    
    February 2017
45. CHOONG ES, Lo S, Drummond M, Fogarty GB, et al
    Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
    Eur J Cancer. 2017;75:169-178.
    PubMed     Text format     Abstract available
    
    
    
46. JANSSENS GO, Gandola L, Bolle S, Mandeville H, et al
    Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
    Eur J Cancer. 2017;73:38-47.
    PubMed     Text format     Abstract available
    
    
    
47. FOSSARD G, Ferlay C, Nicolas-Virelizier E, Rey P, et al
    Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Eur J Cancer. 2017;72:12-19.
    PubMed     Text format     Abstract available
    
    
    
48. MANIAS KA, Gill SK, MacPherson L, Foster K, et al
    Magnetic resonance imaging based functional imaging in paediatric oncology.
    Eur J Cancer. 2017;72:251-265.
    PubMed     Text format     Abstract available
    
    
    January 2017
49. URSU R, Carpentier A, Metellus P, Lubrano V, et al
    Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
    Eur J Cancer. 2017;73:30-37.
    PubMed     Text format     Abstract available
    
    
    
50. TUCHEN M, Wilisch-Neumann A, Daniel EA, Baldauf L, et al
    Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Eur J Cancer. 2017;73:9-21.
    PubMed     Text format     Abstract available
    
    
    
51. KHATUA S, Ramaswamy V, Bouffet E
    Current therapy and the evolving molecular landscape of paediatric ependymoma.
    Eur J Cancer. 2017;70:34-41.
    PubMed     Text format     Abstract available
    
    
    December 2016
52. GENRE L, Roche H, Varela L, Kanoun D, et al
    External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
    Eur J Cancer. 2016;72:200-209.
    PubMed     Text format     Abstract available
    
    
    November 2016
53. OULDAMER L, Bendifallah S, Chas M, Boivin L, et al
    Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
    Eur J Cancer. 2016;69:102-109.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: